EU/3/17/1874 - orphan designation for treatment of haemophilia A

recombinant adeno-associated viral vector serotype 6 encoding the B-domain-deleted human factor VIII

Overview

On 22 May 2017, orphan designation (EU/3/17/1874) was granted by the European Commission to Coté Orphan Consulting UK Limited, United Kingdom, for recombinant adeno-associated viral vector serotype 6 encoding the B-domain-deleted human factor VIII (also known as SB-525) for the treatment of haemophilia A.

The sponsorship was transferred to Sangamo Therapeutics UK LTD, United Kingdom, in June 2018.

In July 2019, TxCell S.A. changed name to Sangamo Therapeutics France S.A.S.

The sponsorship was transferred to Sangamo Therapeutics UK LTD, United Kingdom, in June 2018 and subsequently to TxCell S.A., France, in February 2019.

The sponsorship was transferred to Pfizer Europe MA EEIG, Belgium, in February 2020.

What is haemophilia A?

Haemophilia A is an inherited bleeding disorder that is caused by the lack of factor VIII, which is one of the proteins involved in the blood coagulation (clotting) process. Patients with haemophilia A are more prone to bleeding than normal and bleed for a long time after injury or surgery. Bleeding can also happen within muscles or the spaces in the joints, such as the elbows, knees and ankles. This can lead to permanent injury if it happens repeatedly.

Haemophilia A is a debilitating disease that is life long and may be life threatening because bleeding can happen in the brain, spinal cord or gut.

What is the estimated number of patients affected by the condition?

At the time of designation, haemophilia A affected approximately 1.3 in 10,000 people in the European Union (EU). This was equivalent to a total of around 67,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 515,700,000 (Eurostat 2017).

What treatments are available?

At the time of designation, medicines containing factor VIII were authorised in the EU for the treatment of haemophilia A, to replace the missing protein. However, factor VIII medicines did not work in some patients with haemophilia A because the immune system (the body's natural defences) can produce 'inhibitors' (antibodies) against factor VIII which stop the factor VIII medicine from working. In these cases, other treatments needed to be used, such as factor VIIa (the activated form of factor VII, another protein involved in blood clotting), either alone or as part of a combination treatment.

The sponsor has provided sufficient information to show that this medicine might be of significant benefit for patients with haemophilia A because laboratory studies showed that the medicine could work in a different way to current medicines and reduce bleeding time. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

This medicine consists of a virus that has been modified to contain a gene that produces factor VIII, the protein that is lacking in patients with haemophilia A. When given to patients, the virus is expected to carry this gene into liver cells. This would enable these cells to produce factor VIII, thereby helping the blood to clot and controlling bleeding.

The virus used in this medicine (adeno-associated virus) does not cause disease in humans.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with haemophilia A were planned.

At the time of submission, the medicine was not authorised anywhere in the EU for haemophilia A or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 11 April 2017 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/17/1874: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector serotype 6 encoding the B-domain-deleted human factor VIII for the treatment of haemophilia A

Adopted Reference Number: EMA/260421/2017

Key facts

• Active substance:
  recombinant adeno-associated viral vector serotype 6 encoding the B-domain-deleted human factor VIII
• Intended use:
  Treatment of haemophilia A
• Orphan designation status:
  Positive
• EU designation number:
  EU/3/17/1874
• Date of designation:
  22/05/2017
• Sponsor:

  Pfizer Europe MA EEIG;

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.